- Home
- AMLX vs EYPT Comparison
AMLX vs EYPT Comparison
Compare AMLX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- EYPT
- Stock Information
- Founded
- AMLX 2014
- EYPT 1987
- Country
- AMLX United States
- EYPT United States
- Employees
- AMLX N/A
- EYPT N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- AMLX Health Care
- EYPT Industrials
- Exchange
- AMLX Nasdaq
- EYPT Nasdaq
- Market Cap
- AMLX 684.6M
- EYPT 579.4M
- IPO Year
- AMLX 2022
- EYPT 2005
- Fundamental
- Price
- AMLX $7.72
- EYPT $9.71
- Analyst Decision
- AMLX Strong Buy
- EYPT Strong Buy
- Analyst Count
- AMLX 7
- EYPT 8
- Target Price
- AMLX $12.00
- EYPT $24.75
- AVG Volume (30 Days)
- AMLX 1.5M
- EYPT 636.8K
- Earning Date
- AMLX 08-07-2025
- EYPT 08-06-2025
- Dividend Yield
- AMLX N/A
- EYPT N/A
- EPS Growth
- AMLX N/A
- EYPT N/A
- EPS
- AMLX N/A
- EYPT N/A
- Revenue
- AMLX N/A
- EYPT $56,042,000.00
- Revenue This Year
- AMLX N/A
- EYPT N/A
- Revenue Next Year
- AMLX N/A
- EYPT N/A
- P/E Ratio
- AMLX N/A
- EYPT N/A
- Revenue Growth
- AMLX N/A
- EYPT 12.04
- 52 Week Low
- AMLX $1.76
- EYPT $3.91
- 52 Week High
- AMLX $8.72
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- AMLX 54.70
- EYPT 47.87
- Support Level
- AMLX $7.84
- EYPT $9.77
- Resistance Level
- AMLX $8.29
- EYPT $10.41
- Average True Range (ATR)
- AMLX 0.45
- EYPT 0.52
- MACD
- AMLX -0.13
- EYPT -0.17
- Stochastic Oscillator
- AMLX 2.90
- EYPT 8.58
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.